Information for the Newly Diagnosed

This video contains important information for the newly diagnosed family.

The two featured physicians care for juvenile myositis (JM) patients and explain the following topics:

  • JM basics
  • Common treatments
  • Sun protection
  • Partnering with your medical team
  • Keeping track of medical records
  • Preparing for doctors’ visits
  • Seeking support

Our Two Guest Speakers, include:

  • Megan Curran, MD, is an attending physician in the Section of Rheumatology at Children’s Hospital Colorado and an associate professor at the University of Colorado School of Medicine. She is the Director of the Pediatric Rheumatology Fellowship Program where she organizes the training program for up-and-coming pediatric rheumatologists.
  • Dawn Wahezi, MD, MS, is Division Chief of Pediatric Rheumatology and Director of the Pediatric Rheumatology Fellowship Program at Children’s Hospital at Montefiore. Dr. Wahezi is an Associate Professor of Pediatrics at Albert Einstein College of Medicine.
Executive Director Update - A Season of Gratitude

Season of Gratitude

I am writing to wish you and your family the very best this Holiday Season. This time of year, especially, I am filled with deep appreciation for all that Cure JM families have accomplished to advance our mission, to improve the lives of children living with JM, and to support the doctors and researchers driving better treatments as we fight for a cure.

Affordable and Accessible Treatments for JM

Affordable and Accessible Treatments for JM

Two special guest speakers, Michelle Vogel, MPA, IV Solutions RX, and Laurel Cherwin, BSN, RN, IgCN, Octapharma, shared information on navigating affordable treatments and care for JM patients.

The FDA’s Ruling on Vamorolone in DMD

You may have heard about yesterday’s FDA ruling, which approved vamorolone as an alternative steroid for use in Duchenne muscular dystrophy.

Vamorolone is a new steroid alternative with fewer side effects than prednisone. The drug aims to preserve the beneficial anti-inflammatory and muscle-strengthening characteristics of corticosteroids, while decreasing some of the unwelcome side effects, including bone fragility, delayed growth, and behavior changes.

As we learned in yesterday’s announcement, vamorolone was found to be both safe and effective as a therapy for Duchenne muscular dystrophy in its newly approved indication.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.